Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
To determine the relative bioavailability of the capsule (reference) and tablet (test)
formulations of FDL169 in healthy adult males and females, and to evaluate the
pharmacokinetic (PK) profile FDL169 tablets (test formulation) in both healthy adult males
and females, and subjects with cystic fibrosis (CF).